• SEC Filings

On December 21, 2017, following the completion of the exchange of Series L convertible preferred stock (the “Series L Preferred Stock”) for all outstanding Series F convertible preferred stock (the “Series F Preferred Stock”), Series G convertible preferred stock (the “Series G Preferred Stock”) and Series H convertible preferred stock (the “Series H Preferred Stock”) and related documentation, MabVax Therapeutics Holdings, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificates of Elimination eliminating from its Amended and Restated Certificate of Incorporation the designation of shares of its preferred stock as Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock. As a result, all shares of preferred stock previously designated as Series F, Series G and Series H Preferred Stock were eliminated and returned to the status of authorized but unissued shares of preferred stock, without designation.

A copy of the Certificate of Elimination for the Series F, Series G and Series H Preferred Stock is included in this Current Report as Exhibit 3.1, the contents of which are each hereby incorporated by reference.

MABVAX THERAPEUTICS HOLDINGS, INC. Exhibit
EX-3.1 2 ex3-1.htm CERTIFICATE OF ELIMINATION OF SERIES F,…
To view the full exhibit click here